Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques.
Emerg Microbes Infect
; 11(1): 438-441, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-1662090
ABSTRACT
Mucosal immunity provides a potential for preventing initial infection and stopping subsequent transmission of SARS-CoV-2. Here, we examined the safety and immunogenicity of a replication-defective adenovirus type-5 vectored vaccine (Ad5-nCov) encoding SARS-CoV-2 spike protein delivered by nebulization inhalation in rhesus macaques. The vaccine-associated clinical pathology and toxicity were not observed in the NHP model. The extensive safety study indicated that Ad5-nCoV was mainly confined to the organs related to respiratory system and was rapidly cleared away from the system. Our results showed that Ad5-nCoV delivered by inhalation robustly elicited both systematic and mucosal immune responses against SARS-nCoV-2 and variants. Thus, Ad5-nCoV inhalation may provide an effective, safe and non-invasive vaccination strategy for the control of SARS-CoV-2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Adenoviridae
/
Immunity, Mucosal
/
Spike Glycoprotein, Coronavirus
/
COVID-19 Vaccines
/
Genetic Vectors
/
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic study
/
Systematic review/Meta Analysis
Topics:
Vaccines
/
Variants
Limits:
Animals
/
Humans
Language:
English
Journal:
Emerg Microbes Infect
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS